• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

VoxCell BioInnovation

Wednesday, June 05, 2024
Start-Up Stadium Session
Tools/Drug Development Support Tech
Company Description: VoxCell is creating human-like vascularized tissue models as a screening platform in drug development; by combining Canada’s first high-resolution 3D bioprinter, VoxCell’s proprietary universal bioinks and VoxCell’s vascularization software. These innovations result in fully vascularized and perfusable tissue models, akin to artificial biopsy samples. The problem we target is the alarming 95% failure rate in drug development, which extends from preclinical stages to phase 3 clinical trials, costing an estimated $60 billion USD annually in failed clinical trials in oncology. This high failure rate primarily stems from the absence of reliable tools that can accurately predict drug candidate behavior in human patients. VoxCell's 3D bioprinted vascularized tissue models offer a transformative solution. They enable early identification of unviable drug candidates, allowing pharmaceutical companies to fail faster and more cost-effectively. By doing so, our solution saves time and resources, benefiting both the pharmaceutical industry and patients waiting for more effective treatments.

VoxCell BioInnovation
Company Website: https://www.voxcellbio.com/

Company HQ City

Victoria

Company HQ State

British Columbia

Company HQ Country

Canada

CEO/Top Company Official

Dr. Karolina Valente
Primary Speaker
Kevin Vos
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS